Overview

Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals

Status:
Completed
Trial end date:
2021-04-05
Target enrollment:
Participant gender:
Summary
To find out if it is possible for HIV-1 patients to maintain antiretroviral medications during allogeneic bone marrow transplant
Phase:
Early Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Enfuvirtide